New insider activity at Stoke Therapeutics ( (STOK) ) has taken place on March 21, 2025.
Recent transactions in Stoke Therapeutics stock highlight significant sales by key executives. CMO Barry Ticho sold 7,217 shares, amounting to $61,238. GC & Corp Sec Jonathan Allan offloaded 4,211 shares for $35,731. Meanwhile, Director Edward Kaye sold 19,289 shares, totaling $163,672. These transactions reflect notable movements within the company’s stock by its top leadership.
Recent Updates on STOK stock
In the last 24 hours, Stoke Therapeutics announced its 2024 financial results, revealing a strong cash position of $246.7 million and a strategic collaboration with Biogen to support operations until mid-2028. The company reported Q4 revenue of $22.6 million, significantly surpassing the consensus estimate of $4.28 million, primarily due to upfront license fees and services from a collaboration with Acadia Pharmaceuticals. The announcement of a Phase 3 EMPEROR study for zorevunersen, a treatment for Dravet syndrome, and the transition of Dr. Edward M. Kaye from CEO to an advisory role were key developments. The company’s recent achievements, including a Breakthrough Therapy Designation and positive clinical data, have enhanced its market position and fueled optimism about its lead investigational medicine. These factors, along with the collaboration with Biogen, have contributed to a positive sentiment and a ‘Buy’ rating for the stock.
More about Stoke Therapeutics
YTD Price Performance: -26.71%
Average Trading Volume: 821,949
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $469.8M
Questions or Comments about the article? Write to editor@tipranks.com